last
year
macroalga
attract
increas
attent
mani
industri
divers
branch
fuel
plastic
cosmet
pharmaceut
food
fact
chemic
divers
within
red
rhodophyta
green
chlorophyta
brown
phaeophyta
macroalga
offer
possibl
find
wide
varieti
primari
secondari
metabolit
interest
properti
applic
primari
metabolit
directli
involv
physiolog
function
normal
growth
condit
reproduct
secondari
metabolit
mainli
excretori
product
produc
differ
stress
condit
exposur
ultraviolet
uv
radiat
chang
temperatur
salin
environment
pollut
primari
algal
metabolit
normal
one
protein
polysaccharid
lipid
wherea
main
secondari
metabolit
produc
alga
tissu
phenol
compound
halogen
compound
sterol
terpen
small
peptid
among
bioactiv
compound
studi
focus
prepar
macroalga
extract
chemic
character
reveal
larg
rang
seawe
compound
interest
biolog
activ
includ
antitumor
antiinflammatori
antimicrobi
antidiabet
antiviru
antihypertens
fatlow
neuroprotect
activ
larg
volum
studi
prove
seawe
compound
activ
vitro
system
hint
need
advanc
knowledg
macroalga
compound
effici
live
system
vivo
use
develop
pharmaceut
vitro
studi
relev
yield
import
inform
repres
first
step
long
process
result
obtain
rare
reveal
anyth
effect
compound
vivo
respons
observ
vitro
magnifi
diminish
total
differ
complex
integr
system
fact
vivo
studi
clinic
trial
contribut
truli
understand
real
potenti
compound
futur
pharmaceut
regard
present
work
intend
present
insight
result
obtain
last
year
regard
secondari
metabolit
phlorotannin
halogen
compound
fucoxanthin
fucosterol
isol
macroalga
involv
vivo
studi
clinic
trial
identifi
research
opportun
knowledg
gap
valor
compound
natur
resourc
intent
present
exhaust
survey
publish
work
rather
select
author
base
follow
criteria
indepth
studi
involv
pure
compound
characterist
seawe
studi
appli
dose
less
mgkg
except
justifi
discuss
studi
phloroglucinol
figur
basic
unit
phlorotannin
found
reduc
toxic
zebrafish
treat
group
present
surviv
rate
control
group
augment
surviv
rate
correl
reduct
cell
death
lipid
peroxid
ro
format
moreov
compound
acceler
liver
regener
metronidazol
mnz
induc
apoptosi
concentr
effect
blood
glucos
level
regul
glucos
synthesi
liver
also
investig
shown
tabl
phloroglucinol
mgkg
bw
significantli
improv
glucos
toler
male
mice
whose
diet
high
fat
inhibit
glucos
synthesi
primari
mous
hepatocyt
phlorotannin
also
exert
effici
cell
protect
ioniz
radiat
extend
surviv
mice
expos
lethal
dose
thirti
day
exposur
surviv
rate
group
treat
mgkg
bw
group
treat
mgkg
bw
control
group
mice
surviv
propos
protect
mainli
due
antioxid
effect
name
inhibit
ro
format
lead
inhibit
mitogenactiv
protein
kinas
cjun
kinas
jnk
activ
cascad
moon
et
al
found
administr
mgkg
bw
could
enhanc
jejun
crypt
surviv
decreas
number
apoptot
cell
jejun
crypt
compar
untreat
irradi
group
tabl
phloroglucinol
mgkg
bw
protect
hairless
mice
uvbinduc
photodamag
skin
significantli
reduc
wrinkl
format
epiderm
thick
elast
fiber
degener
level
uvbinduc
dna
damag
also
decreas
sinc
topic
applic
mgmous
found
increas
express
level
xeroderma
pigmentosum
complement
group
c
xpc
excis
repair
crosscomplement
compon
essenti
activ
nucleotid
excis
repair
ner
pathway
mechan
respons
dna
repair
phloroglucinol
also
exhibit
breast
anticanc
activ
mgkg
bw
either
decreas
tumor
growth
suppress
metastat
abil
breast
cancer
cell
spread
lung
contribut
case
increas
surviv
time
mice
tabl
sinc
still
suitabl
therapeut
agent
block
progress
breast
cancer
result
clinic
import
treatment
metastat
breast
cancer
octaphlorethol
rare
phlorotannin
decreas
oxid
stress
induc
either
aaph
high
level
glucos
zebrafish
embryo
tabl
phlorotannin
toxic
embryo
concentr
howev
concentr
lower
strong
antioxid
effect
note
without
trace
toxic
toxic
valu
zebrafish
support
data
obtain
kim
et
al
found
subject
embryo
surviv
upon
exposur
concentr
significantli
differ
find
control
group
moreov
author
report
compound
significantli
inhibit
melanin
synthesi
tyrosinas
activ
concentr
higher
inhibit
obtain
refer
compound
arbutin
melanin
synthesi
tyrosinas
activ
respect
result
indic
potenti
applic
skinwhiten
formul
dose
mgkg
bw
led
reduct
mmhg
systol
blood
pressur
sbp
spontan
hypertens
rat
shr
mmhg
reduct
obtain
use
dosag
refer
drug
captopril
antihypertens
effect
maintain
h
author
suggest
effect
due
induct
product
vasodil
diphlorethohydroxycarmalol
isol
ishig
okamura
yendo
protect
effect
radiat
exposur
ahn
et
al
report
treatment
mgkg
bw
mice
irradi
significantli
protect
intestin
crypt
cell
jejunum
maintain
villi
height
compar
controltr
irradi
group
mice
pretreat
also
exhibit
dosedepend
increas
bone
marrow
cell
viabil
maximum
mgkg
bw
diphlorethohydroxycarmalol
decreas
oxid
stress
caus
skin
tissu
hairless
mice
fine
particul
matter
diamet
major
pollut
present
atmospher
tabl
exposur
caus
lipid
peroxid
protein
carbonyl
increas
epiderm
height
inhibit
moreov
induc
apoptosi
mitogenactiv
protein
kinas
mapk
protein
express
howev
chang
attenu
fernando
et
al
report
first
time
use
zebrafish
embryo
model
evalu
inflammatori
effect
fine
dust
fd
particl
major
aggress
agent
air
pollut
author
determin
concentr
significantli
decreas
ro
product
prevent
fine
dust
inflammationinduc
cell
death
effect
high
glucoseinduc
angiogenesi
zebrafish
embryo
studi
found
treatment
embryo
concentr
suppress
high
glucoseinduc
dilat
retin
vessel
diamet
vessel
format
tabl
moreov
exhibit
abil
inhibit
high
glucoseinduc
vascular
endotheli
growth
factor
receptor
express
downstream
signal
cascad
henc
seem
potenti
agent
develop
drug
angiogenesi
induc
diabet
eckol
present
antiinflammatori
activ
variou
vivo
studi
kim
et
al
found
concentr
significantli
suppress
acet
acidinduc
hyperperm
carboxymethylcelluloseinduc
leucocyt
migrat
mice
much
higher
level
tabl
dosag
nmol
per
mous
decreas
mous
ear
edema
induc
differ
sensit
arachidon
acid
aa
tpa
oxazolon
oxa
respect
tabl
show
modul
variou
target
inflammatori
cascad
hand
low
dosag
mgkg
bw
hepatoprotect
effect
mice
modul
antiapoptot
antioxid
mechan
suppress
express
proinflammatori
cytokin
like
tumor
necrosi
factor
tnf
interleukin
il
upregul
express
antiinflammatori
interleukin
kim
et
al
report
present
anticoagul
activ
mous
model
dosag
mgkg
bw
increas
vivo
tail
bleed
time
increas
howev
result
lower
obtain
heparin
commerci
anticoagul
eckol
mgkg
bw
also
significantli
reduc
level
triglycerid
tg
total
cholesterol
tc
atherogen
index
ai
lowdens
lipoprotein
cholesterol
ldl
increas
level
highdens
lipoprotein
cholesterol
hdl
sd
rat
similar
valu
present
lovastatin
tabl
therapeut
agent
use
treatment
hypercholesterolemia
park
et
al
found
administr
mgkg
bw
irradi
mice
led
improv
hematopoiet
recoveri
repair
damag
dna
immun
cell
enhanc
prolifer
sever
suppress
ioniz
radiat
tabl
also
found
dose
decreas
lymphocyt
apoptosi
intestin
cell
apoptosi
correl
decreas
amount
proapoptot
bax
protein
increas
level
antiapoptot
protein
indic
overexpress
lead
resist
dna
damag
involv
protect
gastrointestin
cell
irradi
furthermor
moon
et
al
found
higher
dose
mgkg
bw
enhanc
jejun
crypt
surviv
protect
apoptosi
induc
radiat
icr
mice
jejun
crypt
albeit
lesser
extent
valu
obtain
tabl
find
indic
candid
adjuv
therapi
allevi
radiationinduc
injuri
cancer
patient
howev
far
abl
assess
advanc
regard
pretreat
reduc
ro
format
respect
zebrafish
embryo
follow
uvb
irradi
also
reduc
uvbinduc
cell
death
hyperpigment
compar
untreat
control
group
show
photoprotect
effect
compound
present
low
toxic
test
concentr
dieckol
abl
impair
oxid
stress
effect
induc
ethanol
zebrafish
embryo
concentr
decreas
ro
format
lipid
peroxid
attenu
oxid
stress
led
decreas
ethanolinduc
liver
cell
death
show
dieckol
possess
hepatoprotect
effect
dieckol
dose
also
decreas
oxid
effect
caus
high
glucos
significantli
reduc
heart
rate
ro
lipid
peroxid
cell
death
zebrafish
tabl
furthermor
high
glucos
level
induc
overexpress
induc
nitric
oxid
synthas
ino
wherea
treatment
reduc
addit
antioxid
effect
also
play
import
role
attenu
type
ii
diabet
diabet
mice
inject
mgkg
bw
show
signific
reduct
blood
glucos
level
serum
insulin
level
bodi
weight
compar
untreat
group
nonetheless
also
promot
increas
activ
antioxid
enzym
includ
superoxid
dismutas
sod
catalas
cat
glutathion
peroxidas
gshpx
liver
tissu
increas
level
phosphoryl
ampk
akt
muscl
tissu
tabl
suggest
develop
therapeut
agent
type
ii
diabet
like
phlorotannin
also
suppress
acet
acidinduc
hyperperm
carboxymethylcelluloseinduc
leucocyt
migrat
mice
albeit
higher
level
lead
conclus
number
oh
group
structur
increas
antiinflammatori
activ
author
prove
influenc
oh
group
activ
protect
group
methyl
substitu
activ
obtain
methyldieckol
reduc
comparison
also
verifi
anticoagul
activ
kim
et
al
found
increas
vivo
tail
bleed
time
wherea
increas
time
heparin
increas
tail
bleed
time
dieckol
also
present
better
potenti
treat
dyslipidemia
sinc
reduc
paramet
measur
yoon
et
al
higher
level
obtain
even
lovastatin
tabl
exampl
effici
treatment
dyslipidemia
dose
mgkg
bw
decreas
total
cholesterol
compar
untreat
group
wherea
lovastatin
mgkg
bw
decreas
paramet
dieckol
also
present
antiallergi
effect
sinc
oral
administr
mgkg
bw
ige
sensit
markedli
abrog
mast
cell
degranul
edemat
chang
vivo
howev
author
also
suggest
inhibit
passiv
cutan
anaphylaxi
could
mainli
attribut
antiinflammatori
effect
literatur
revis
perform
present
work
phlorotannin
alreadi
known
found
vitro
activ
report
one
two
studi
address
vivo
activ
unlik
compound
discuss
howev
activ
interest
thu
studi
address
less
studi
phlorotannin
discuss
demonstr
interest
futur
studi
phlorotannin
phlorofucofuroeckol
b
suppress
ear
swell
mice
induc
aa
tpa
oxa
respect
tabl
wherea
suppress
ear
edema
induc
three
sensit
show
significantli
lower
isom
indic
chang
group
increas
compound
antiinflammatori
capac
result
present
also
better
obtain
tabl
interest
activ
shown
vivo
phlorotannin
justifi
realiz
studi
includ
deep
sar
studi
establish
action
mechan
administr
figur
mous
nmol
per
mous
caus
reduct
ear
swell
sensit
aa
tpa
respect
antiinflammatori
effect
similar
phlorofucofuroeckol
b
although
much
smaller
antiinflammatori
effect
oxainduc
mous
model
hand
administr
abl
inhibit
mous
ear
swell
sensit
oxa
highest
valu
obtain
sugiura
et
al
administr
yield
inhibit
result
show
clearli
posit
linkag
great
influenc
antiinflammatori
activ
phlorotannin
compound
exhibit
antiinflammatori
effect
ident
higher
epigallocatechin
gallat
egcg
compound
use
posit
control
ko
et
al
found
dose
mgkg
bw
led
reduct
mmhg
sbp
shr
wherea
dosag
refer
drug
captopril
decreas
sbp
mmhg
phlorotannin
less
activ
octaphlorethol
sinc
dose
use
two
time
higher
dose
tabl
thu
latter
seem
promis
antihypertens
applic
phlorotannin
eckstolonol
significantli
decreas
sleep
latenc
concentrationdepend
manner
increas
amount
nonrapid
eye
movement
nrem
mice
mgkg
bw
dose
administ
conjunct
pentobarbit
also
capabl
increas
sleep
durat
compar
control
pentobarbit
show
phlorotannin
also
potenti
effect
hypnot
drug
found
act
partial
agonist
receptor
similar
action
mode
benzodiazepin
show
potenti
hypnot
drug
addit
good
result
present
phlorotannin
vivo
studi
show
high
pharmaceut
potenti
studi
inform
actual
amount
compound
administ
hinder
comparison
studi
well
reproduc
result
also
major
referenc
studi
particularli
use
murin
model
small
group
individu
per
studi
group
may
repres
real
effect
compound
futur
studi
increas
number
test
subject
increas
statist
power
find
one
biolog
interest
famili
peptid
extract
macroalga
lectin
structur
divers
group
highli
specif
revers
carbohydratebind
protein
three
group
macroalga
rhodophyta
phaeophyta
chlorophyta
produc
lectin
lectin
present
great
potenti
develop
new
drug
fact
highli
specif
way
lectin
bind
sugar
outsid
cell
surfac
inhibit
cell
prolifer
lectin
primarili
show
antivir
antibacteri
antifung
activ
interest
lectin
also
one
vivo
studi
griffithsin
figur
tabl
griffithsin
first
isol
aqueou
extract
griffithsia
sp
exhibit
antivir
activ
peptid
show
signific
homolog
known
protein
exhibit
potent
vitro
antivir
activ
valu
rang
nm
entic
research
perform
sever
subsequ
vivo
studi
keef
et
al
report
antivir
effect
griffithsin
figur
tabl
mous
model
infect
adapt
sarscov
viru
inject
viral
dose
known
caus
least
mous
mortal
mice
treat
griffithsin
mgkg
bw
dose
intranas
deliv
h
infect
show
surviv
rate
weight
loss
decreas
pulmonari
patholog
infect
compound
reduc
mice
pulmonari
viral
load
inhibit
deleteri
inflammatori
respons
viru
ishag
et
al
prove
griffithsin
lifesav
vivo
efficaci
mice
model
infect
lethal
dose
japanes
enceph
viru
jev
similar
result
obtain
keef
et
al
treat
mice
show
surviv
rate
well
reduc
viral
antigen
load
brain
tissu
griffithsin
treatment
mice
consist
mgkg
bw
intraperiton
inject
enceph
viru
fact
mgkg
bw
dose
effect
sarscov
jev
viru
highlight
griffithsin
potenti
antivir
agent
subsequ
meuleman
et
al
also
use
mgkg
bw
griffithsin
treatment
subcutan
inject
chimer
upascid
mice
mitig
hepat
c
liver
infect
one
week
viru
inject
result
show
significantli
lower
viral
load
limit
detect
iuml
four
six
treat
mice
oppos
easili
detect
load
control
mice
follow
two
week
studi
treat
mice
start
slowli
exhibit
sign
infect
control
mice
experienc
fullblown
viremia
surprisingli
one
treat
mice
manag
stay
complet
detect
limit
throughout
entir
studi
period
result
point
extent
versatil
griffithsin
antivir
activ
taxonom
distinct
virus
although
interest
result
feel
particularli
limit
scope
due
small
sampl
size
n
treat
n
control
mice
fact
acknowledg
author
nevertheless
griffithsin
broadspectrum
antivir
action
still
allur
research
beg
studi
nixon
et
al
use
murin
model
see
griffithsin
gel
would
protect
mice
intravagin
appli
genit
herp
result
show
gel
significantli
prevent
herp
simplex
viru
infect
prolifer
mucos
surfac
challeng
subsequ
viral
introduct
semin
plasma
result
complement
obtain
keef
et
al
use
rabbit
vagin
irrit
model
prove
griffithsin
safeti
topic
microbicid
compon
result
show
griffithsin
caus
mucos
damag
inflammatori
respons
anoth
studi
levendoski
et
al
use
similar
intravagin
challeng
methodolog
assess
topic
appli
antivir
activ
combin
herp
simplex
human
papillomaviru
dose
combin
cg
shown
scientif
reduc
vagin
infect
appli
challeng
dose
challeng
discrep
efficaci
timefram
believ
due
severalhour
lag
period
hpv
replic
cycl
notwithstand
result
line
previou
work
prove
griffithsin
action
broadspectrum
antivir
conclud
present
recent
studi
girard
et
al
produc
rectal
appli
griffithsin
gel
rhesu
monkey
studi
confirm
safeti
griffithsin
antihiv
agent
minimum
disturb
monkey
rectal
proteom
microbiota
summari
griffithsin
show
tremend
promis
topic
antivir
agent
great
potenti
concern
prevent
sexual
transmit
infect
compound
repeatedli
proven
efficaci
along
safeti
studi
keef
et
al
girard
et
al
appear
lead
preclin
stage
test
happen
soon
eventu
pave
way
futur
clinic
trial
search
angiotensinconvert
enzym
ace
inhibitor
great
biolog
valu
due
inher
hypotens
effect
subsequ
applic
macroalga
proven
especi
rich
sourc
compound
ace
inhibit
activ
regard
seawe
ace
renin
inhibitor
review
choos
focu
irliivlmpilma
tridecapeptid
dipeptid
figur
shown
tabl
mainli
due
potent
hypotens
activ
compar
current
pharmaceut
option
captopril
well
recent
relev
interest
fitzgerald
et
al
studi
hypotens
effect
renin
inhibitor
tridecapeptid
irliivlmpilma
figur
previous
extract
purifi
palmaria
palmata
linnaeu
f
weber
mohr
hydrolys
use
shr
model
research
group
report
dose
mgkg
bw
tridecapeptid
result
decreas
sbp
mmhg
h
especi
interest
compar
posit
control
clinic
hypotens
drug
captopril
show
sbp
decreas
mmhg
dose
also
noteworthi
sbp
decreas
achiev
palmaria
palmata
linnaeu
f
weber
mohr
protein
hydrolys
dose
mgkg
bw
shr
model
also
use
somewhat
similar
studi
sato
et
al
test
ace
inhibitori
peptid
purifi
undaria
pinnatifida
harvey
suringar
hydrolys
seven
dipeptid
identifi
test
vivo
dipeptid
stood
reveal
statist
signific
sbp
decreas
h
mgkg
bw
dose
sbp
decreas
h
mgkg
bw
dose
result
compar
captopril
show
sbp
decreas
h
respect
mgkg
bw
dose
recent
work
et
al
studi
poli
lacticcoglycol
acid
nanoparticl
deliveri
system
dipeptid
highlight
continu
interest
relev
seawe
peptid
great
antihypertens
potenti
previous
mention
analyz
literatur
irliivlmpilma
tridecapeptid
dipeptid
figur
tabl
promis
vivo
hypotens
seawe
compound
identifi
far
similar
effect
clinic
drug
phycoerythrin
figur
red
protein
pigment
complex
abund
rhodophyta
although
mani
studi
use
cyanobacteria
readili
avail
natur
sourc
compound
anoth
polypeptid
interest
hypotens
agent
rather
antitumor
antiag
agent
extens
vitro
studi
demonstr
cytotox
activ
phycoerythrin
figur
pan
et
al
demonstr
activ
vivo
use
tumorbear
mice
model
tabl
result
show
phycoerythrin
inject
dose
mgkg
bw
reduc
tumor
growth
treat
mice
mice
also
reveal
signific
serum
increas
level
nk
cell
kill
activ
lymphocyt
prolifer
antitumor
activ
obtain
believ
relat
phycoerythrin
antioxid
activ
shown
signific
increas
superoxid
dismutas
activ
serum
treat
mice
well
signific
decreas
mous
liver
malondialdehyd
level
shortli
sonani
et
al
use
caenorhab
elegan
model
test
vivo
antioxid
antiag
effect
phycoerythrin
dose
compound
found
significantli
increas
caenorhab
elegan
lifespan
normal
oxid
stress
condit
indic
phycoerythrin
strong
antiag
effect
possibl
relat
antioxid
properti
recent
work
chaubey
et
al
test
effect
phycoerythrin
mutant
caenorhab
elegan
alzheim
diseas
model
result
show
dose
phycoerythrin
led
signific
reduct
senil
plaqu
format
compar
untreat
nematod
indic
phycoerythrin
might
great
potenti
therapeut
agent
neurodegen
diseas
test
requir
confirm
kahalalid
f
figur
cyclic
depsipeptid
belong
kahalalid
protein
famili
first
describ
hamann
scheuer
isol
bryopsi
sp
green
alga
well
elysia
rufescen
mollusk
feed
bryopsi
bioaccumul
studi
use
mollusk
sourc
compound
vitro
studi
reveal
great
cytotox
potenti
sever
tumor
cell
line
particularli
prostat
breast
cancer
line
valu
rang
vivo
studi
carri
faircloth
cueva
show
tumor
respons
inject
figur
tabl
human
breast
prostat
colon
lung
tumor
cell
xenograft
athym
mice
treatment
mgkg
bw
dose
led
smaller
chemotherapyresist
prostat
tumor
human
prostat
tumor
reduc
nearli
mgkg
bw
dose
highli
promis
result
led
kahalalid
f
clinic
trial
phase
discuss
later
halogen
compound
also
interest
set
bioactiv
macroalga
secondari
metabolit
among
halogen
terpen
bromophenol
whose
vivo
studi
reveal
greatest
potenti
new
drug
develop
discuss
pentahalogen
monoterpen
bromomethyl
known
trivial
name
halomon
figur
tabl
show
promis
vitro
cytotox
studi
submicromolar
valu
go
far
select
nation
cancer
institut
within
human
tumor
cell
line
anticanc
drug
screen
program
preclin
studi
drug
develop
although
test
never
went
beyond
preliminari
phase
first
result
promis
show
appar
cure
aggress
brain
tumor
mous
ipip
xenograft
model
latest
publish
result
regard
preclin
trial
process
relat
halomon
test
mice
regard
bioavail
pharmacokinet
tissu
distribut
result
show
halomon
bioavail
higher
intraperiton
inject
subcutan
inject
respect
urinari
excret
minim
halomon
distribut
tissu
higher
concentr
adipos
tissu
concentr
halomon
measur
brain
compar
detect
plasma
tissu
even
though
preclin
test
never
progress
beyond
preliminari
stage
never
deter
scientif
commun
interest
time
recent
studi
action
mechan
propos
act
dna
methyl
inhibitor
howev
deep
mechan
studi
perform
addit
studi
real
obstacl
overcom
halomon
alway
obtain
enough
quantiti
compound
fuller
et
al
describ
struggl
state
slight
geograph
andor
tempor
chang
would
dramat
affect
terpen
content
portieria
hornemanii
altern
approach
consid
natur
problem
led
chemist
tri
synthes
halomon
first
success
occur
schlama
et
al
report
overal
yield
result
obtain
sotokawa
et
al
reduc
previou
process
three
step
report
overal
yield
poor
select
first
effici
highselect
method
describ
bucher
et
al
process
sinc
optim
landri
burn
final
overcom
obstacl
year
halomon
vivo
studi
restart
final
confirm
potenti
anoth
highli
interest
compound
neorogioltriol
figur
tabl
tricycl
bromin
diterpenoid
first
isol
laurencia
glandulifera
chatter
et
al
research
group
show
neorogioltriol
analges
properti
writh
test
neorogiotriol
produc
dosedepend
respons
dose
mgkg
bw
enough
reduc
mous
acet
acidinduc
writh
respons
tabl
rat
model
formalin
test
use
determin
compound
affect
neurogen
andor
inflammatori
pain
result
show
neorogiotriol
reduc
lick
time
second
phase
formalin
test
indic
compound
peripher
analges
effect
act
inflammatori
pain
way
typic
cyclooxygenas
inhibitor
chatter
et
al
supplement
previou
work
neorogioltriol
test
vivo
antiinflammatori
effect
induc
rat
paw
swell
result
show
inject
dose
mgkg
bw
compound
reduc
paw
swell
first
hour
three
hour
achiev
antiinflammatori
result
refer
compound
acetylsalicyl
acid
would
requir
dose
mgkg
bw
recent
paper
publish
daskalaki
et
al
studi
two
diterpen
neorogioldiol
figur
tabl
compound
use
treat
mice
dssinduc
inflammatori
bowel
diseas
coliti
mgmous
dose
compound
intraperiton
inject
everi
h
two
differ
group
result
show
treat
mice
demonstr
reduc
inflammatori
colon
tissu
damag
well
signific
decreas
proinflammatori
cytokin
messeng
rna
mrna
decreas
case
neorogioldiol
show
similar
activ
level
reveal
great
potenti
bowel
diseas
inflammatori
treatment
studi
pursu
particularli
assess
neorogiotriol
activ
previous
mention
coliti
model
structur
relat
compound
bromophenol
anoth
class
interest
macroalga
metabolit
although
studi
famili
compound
show
vitro
effect
far
reach
level
evalu
vivo
model
one
biolog
relev
compound
bdde
figur
tabl
first
isol
kurihara
et
al
rhodophyta
odonthalia
corymbifera
research
show
bdde
inhibitor
promis
vitro
studi
confirm
interact
show
anticanc
antifung
activ
recent
publish
studi
show
vivo
antidiabet
activ
research
group
show
dose
mgkg
bw
oral
administ
effect
lower
blood
glucos
level
dbdb
mice
metformin
clinic
antidiabet
drug
studi
also
show
significantli
reduc
glycat
hemoglobin
triglycerid
level
bodi
weight
without
influenc
mice
food
water
intak
show
might
constitut
power
antidiabet
drug
futur
test
requir
ascertain
possibl
anoth
interest
vivo
studi
use
differ
anim
model
also
publish
qi
et
al
reveal
differ
effect
work
bdde
exhibit
potent
angiogenesi
inhibit
activ
zebrafish
embryo
model
work
research
monitor
embryon
develop
zebrafish
subintestin
vessel
siv
incub
presenc
result
show
statist
signific
dosedepend
respons
mm
reduc
siv
growth
respect
unequivoc
prove
effect
antiangiogenesi
agent
point
great
potenti
cancer
therapeut
applic
howev
vivo
antitumor
studi
necessari
summari
consider
divers
alga
halogen
secondari
metabolit
interest
promis
bioactiv
might
lead
futur
drug
develop
howev
test
requir
concern
algal
lipid
fucoxanthin
figur
xanthophylllik
carotenoid
one
studi
metabolit
benefici
health
effect
inde
mani
publish
review
research
articl
demonstr
extol
among
other
nutraceut
antioxid
anticanc
antiobes
antidiabet
antimicrobi
cardiovascular
protect
effect
fucoxanthin
intend
review
relev
vivo
studi
pure
fucoxanthin
highlight
impact
one
process
develop
fucoxanthin
drug
mani
potenti
therapeut
use
fucoxanthin
figur
seem
neuroprotect
effect
evidenc
hu
et
al
use
middl
cerebr
arteri
occlus
rat
model
mcao
assess
neuroprotect
effect
rat
intragastr
administ
differ
dose
mgkg
bw
pure
fucoxanthin
h
cerebr
ischemia
induc
result
show
signific
dosedepend
reduct
neurolog
deficit
score
percentag
infarct
area
brain
well
attenu
brain
edema
one
critic
could
made
research
work
pertain
present
object
result
essay
result
present
graph
form
support
tabl
list
valu
make
hard
properli
object
assess
degre
neurolog
paramet
test
show
improv
nonetheless
publish
work
serv
firmli
support
fucoxanthin
potenti
neuroprotect
supplement
interest
anoth
highli
interest
potenti
pharmaceut
applic
fucoxanthin
illustr
recent
publish
work
wang
et
al
report
fucoxanthin
antitumor
activ
novel
lymphangiogenesi
inhibit
perspect
work
breast
cancer
xenograft
model
use
balbc
nude
mice
treat
dose
fucoxanthin
inject
daili
tumor
peripheri
tumor
excis
day
result
reveal
signific
decreas
microlymphat
vascular
densiti
averag
lymphat
vessel
fucoxanthin
treatment
treatment
per
tumor
tumor
weight
volum
also
decreas
half
dosedepend
manner
although
difficult
assess
reduct
precis
due
lack
valu
tabl
accompani
result
graph
howev
result
adequ
highlight
potenti
cancer
treatment
anoth
studi
terasaki
et
al
antitumor
activ
test
time
colorect
cancer
mous
model
work
aomdss
mice
inject
mgkg
bw
daili
dose
fucoxanthin
oil
seven
week
subsequ
bowel
excis
analysi
post
sacrific
result
show
significantli
reduc
number
colon
polyp
close
half
compar
nontreat
mice
polyp
size
also
significantli
reduc
onethird
control
mice
object
histolog
examin
show
reduct
preval
tumor
ulcer
crypt
dysplasia
author
suggest
may
link
promot
anoikislik
cell
death
support
hypothesi
show
increas
express
key
molecular
hallmark
anoiki
treat
mice
colon
cell
result
reinforc
good
candid
possibl
anticanc
drug
addit
bioactiv
paper
jiang
et
al
highlight
potenti
antidepress
work
lipopolysaccharideinduc
depressivelik
behavior
mous
model
use
evalu
treatment
would
reduc
depress
anxieti
associ
behavior
result
show
treat
mice
significantli
higher
bodi
weight
food
intak
control
mice
well
significantli
reduc
depressivelik
behavior
anxietylik
behavior
behavior
assess
present
mice
stress
conditionsobstacl
evalu
activ
import
note
lower
dose
use
work
show
margin
depress
behavior
reduct
highest
dose
test
mgkg
bw
manag
reduc
depress
anxietylik
behavior
almost
baselin
valu
nondepress
mice
word
mgkg
bw
dose
significantli
reduc
depress
behavior
trait
point
induc
depress
practic
cure
dosag
consider
higher
use
previous
mention
studi
chose
highlight
neuroprotect
bioactiv
due
novelti
rel
relev
final
anoth
studi
su
et
al
reveal
great
potenti
antiinflammatori
mous
sepsi
model
work
lipopolysaccharid
use
albeit
much
higher
dose
previou
studi
induc
sepsi
eventu
lead
death
mous
model
result
show
mgkg
bw
dose
lp
caus
surviv
rate
mice
dose
mice
treat
mgkg
bw
surviv
rate
singl
small
dose
inject
min
prior
challeng
effect
doubl
surviv
rate
sepsi
mous
model
addit
treat
mice
also
show
significantli
reduc
level
proinflammatori
cytokin
reduct
reduct
compar
nontreat
mice
well
significantli
inhibit
inflammatori
pathway
shown
reduct
show
exhibit
potent
antiinflammatori
effect
effect
strong
protect
effect
acut
inflammatori
diseas
model
summari
exhibit
multitud
interest
divers
potent
bioactiv
studi
recent
publish
scientif
commun
appear
great
interest
compound
hope
see
highqual
vivo
public
near
futur
fucosterol
figur
phytosterol
mostli
isol
brown
alga
rel
abund
particular
algal
class
wide
studi
regard
vitro
health
effect
howev
vivo
evalu
fucosterol
health
effect
scarc
regard
present
work
review
exist
vivo
studi
main
observ
conclus
discuss
paragraph
one
first
evalu
vivo
effect
fucosterol
regard
antidiabet
effect
found
administ
oral
mgkg
streptozotocininduc
diabet
rat
fucosterol
caus
signific
decreas
serum
glucos
concentr
exhibit
inhibit
sorbitol
accumul
lens
compar
untreat
group
phytosterol
present
antitumor
activ
vivo
dosag
mgkg
bw
reduc
tumor
weight
tumor
volum
six
week
lung
cancer
xenograft
mice
model
addit
fucosterol
mgkg
bw
reduc
express
indic
cell
prolifer
increas
cleav
level
indic
act
tumor
cell
simultan
decreas
prolifer
enhanc
apoptosi
fucosterol
also
exhibit
protect
effect
lpsinduc
acut
lung
injuri
ali
modul
express
proinflammatori
factor
dosag
mgkg
bw
attenu
lung
histopatholog
chang
wettodri
ratio
lung
lpsinduc
ali
mice
furthermor
fucosterol
significantli
inhibit
tnfa
level
bronchoalveolar
lavag
fluid
balf
lpsstimul
alveolar
macrophag
reduc
express
compar
untreat
group
fact
abl
inhibit
product
proinflammatori
molecul
suggest
could
use
treatment
inflammatori
diseas
suggest
confirm
find
mo
et
al
observ
fucosterol
attenu
serum
liver
enzym
level
hepat
necrosi
apoptosi
induc
fact
dosag
mgkg
bw
fucosterol
reduc
serum
level
three
proinflammatori
molecul
respect
h
exposur
concanavalina
induc
acut
liver
injuri
author
also
found
mgkg
bw
also
inhibit
apoptosi
autophagi
upregul
increas
decreas
level
function
bax
furthermor
reduc
mapk
signal
accompani
activ
show
fucosterol
act
inhibit
signal
fucosterol
abl
reduc
effect
postmenopaus
osteoporosi
studi
perform
ovariectom
rat
found
bone
miner
densiti
femor
bone
significantli
higher
mgkg
bw
treat
group
untreat
group
addit
bodi
weight
six
week
treatment
lower
fucosterol
treat
group
compar
untreat
group
term
serum
biomark
bone
format
resorpt
mgkg
bw
tripl
level
serum
osteocalcin
rel
untreat
group
reduc
serum
level
ctx
suggest
fucosterol
potenti
activ
osteoblast
stimul
bone
format
suppress
differenti
osteoclast
reduc
bone
resorpt
term
neurolog
effect
fucosterol
compound
found
attenu
cognit
impair
age
rat
fact
age
rat
treat
perform
poorli
acquisit
train
memori
test
wherea
coinfus
four
week
assay
restor
rat
perform
level
healthi
control
fucosterol
action
via
downregul
express
upregul
matur
brainderiv
neurotroph
factor
bdnf
express
dentat
gyru
mean
abl
suppress
aginginduc
endoplasm
reticulum
er
stress
fucosterolinduc
upregul
bdnf
level
also
link
neurolog
action
like
antidepress
activ
fact
mgkg
bw
administr
balb
mice
reduc
immobl
time
forc
swim
test
measur
depress
valu
similar
obtain
posit
control
fluoxetin
concentr
effect
observ
tail
suspens
test
fucosterol
fluoxetin
mgkg
bw
significantli
shorten
immobl
time
forc
tail
suspens
test
approxim
compar
untreat
group
fucosterol
mgkg
bw
significantli
increas
serotonin
norepinephrin
metabolit
acet
acid
mous
brain
level
close
observ
brain
mice
subject
stress
tail
suspens
forc
swim
test
suggest
effect
fucosterol
may
mediat
neurotransmitt
also
signific
increas
hippocamp
brainderiv
neurotroph
factor
bdnf
level
found
fucosterol
mgkg
bw
group
suggest
antidepress
effect
may
mediat
increas
central
bdnf
level
find
present
show
could
effici
therapeut
agent
wide
array
health
condit
regardless
number
vivo
test
exist
algal
metabolit
still
scarc
thu
suggest
futur
work
invest
assess
full
vivo
potenti
fucosterol
abovement
inform
regard
perform
seawe
compound
deriv
vivo
assay
show
type
compound
great
pharmaceut
potenti
alreadi
clinic
trial
phase
fucoxanthin
figur
one
two
studi
schedul
begin
end
one
phase
ii
studi
aim
fucoxanthin
effect
metabol
syndrom
clinicaltrialsgov
identifi
test
oral
dietari
supplement
rich
fucoxanthin
improv
liver
health
clinicaltrialsgov
identifi
addit
trial
alreadi
reach
end
present
result
hito
shimoda
report
month
treatment
mg
per
day
weight
loss
effect
mildli
obes
japanes
adult
bmi
sinc
reduc
abdomin
fat
bodi
weight
overal
bmi
compar
placebo
group
result
accord
describ
abidov
et
al
perform
clinic
trial
women
use
dietari
supplement
name
xanthigen
compos
pomegran
seed
oil
brown
seawe
extract
contain
mg
increas
rest
energi
expenditur
induc
bodi
fat
reduct
weight
loss
obes
women
bmi
kahalalid
f
figur
alreadi
mention
section
promis
peptid
test
clinic
trial
particularli
antitumor
properti
colleagu
investig
respons
patient
advanc
malign
melanoma
weekli
intraven
administr
patient
refus
unaccept
toxic
diseas
progress
observ
result
indic
contrari
major
chemotherapeut
agent
induc
sever
cardiac
renal
bone
marrow
toxic
alopecia
diarrhea
mucos
abl
stabil
diseas
three
month
five
patient
complet
studi
recent
studi
evalu
weekli
intraven
administr
maximum
toler
dose
infus
time
recommend
appropri
dose
treatment
time
phase
ii
clinic
studi
patient
advanc
solid
tumor
base
result
author
recommend
dose
three
hour
treatment
per
week
howev
prolong
infus
time
ie
treatment
also
feasibl
unfortun
two
compound
mention
section
reach
clinic
trial
could
due
divers
complic
like
obtain
necessari
approv
requir
start
studi
obtain
volunt
isol
compound
interest
suffici
quantiti
allow
studi
unfold
hand
sinc
seawe
repres
good
sourc
compound
pharmaceut
potenti
sinc
seawe
attain
interest
western
countri
diet
major
clinic
trial
current
carri
ascertain
extent
consumpt
alga
improv
human
health
thu
clinic
trial
discuss
focus
test
effect
consum
one
type
seawe
mixtur
variou
rich
fractionsextract
quick
search
clinicaltrialsgov
possibl
find
clinic
trial
seaweedrelev
clinic
trial
two
activ
ongo
six
schedul
start
shortli
show
current
interest
relev
topic
unfortun
alreadi
complet
clinic
trial
eight
result
publish
addit
possibl
find
clinic
trial
list
databas
contribut
also
overview
topic
grow
interest
sever
clinic
studi
aim
evalu
effect
polysaccharid
fraction
extract
even
whole
seawe
treatment
prevent
diabet
obes
import
aspect
beyond
scope
review
topic
refer
reader
interest
public
subject
recent
studi
conduct
murray
et
al
found
singl
dose
mg
polyphenolrich
fucu
vesiculosu
linnaeu
extract
addit
lower
effect
compar
placebo
postprandi
blood
glucos
plasma
insulin
healthi
adult
author
suggest
futur
studi
polyphenolrich
marin
algal
extract
aim
investig
glycem
modul
effect
atrisk
popul
prediabet
sinc
result
may
differ
anoth
clinic
trial
year
examin
healthi
adult
effect
brown
seawe
extract
consumpt
postprandi
cognit
function
dose
brown
seawe
extract
mg
contain
phlorotannin
consum
min
lunch
attent
episod
memori
subject
state
paramet
analyz
five
time
period
follow
lunch
interv
measur
result
demonstr
improv
cognit
perform
follow
ingest
seawe
extract
compar
placebo
group
sinc
accuraci
increas
choic
reaction
time
digit
vigil
task
author
point
sinc
brown
seawe
extract
supplement
equival
g
dri
seawe
cognit
benefit
present
work
could
obtain
dietari
intak
seawe
consumpt
regard
seawe
consumpt
anoth
studi
investig
accept
ascophyllum
nodosum
linnaeu
le
jolisenrich
bread
part
meal
overweight
healthi
male
see
could
modul
cholesterolem
glycem
respons
reduc
energi
intak
four
hour
enrich
bread
consumpt
breakfast
use
test
meal
energi
intak
suffer
signific
reduct
accord
studi
result
accept
incorpor
seawe
basic
food
bread
least
concentr
wholem
loaf
consid
interest
result
acut
feed
trial
author
accentu
longterm
studi
regard
addit
seaweedenrich
bread
diet
particip
would
help
clarifi
potenti
reduct
energi
intak
potenti
posit
affect
bodi
mass
index
bmi
higher
oxid
statu
increas
oxid
damag
macromolecul
associ
obes
increas
probabl
chronic
diseas
develop
obes
individu
risk
group
baldrick
et
al
investig
bioavail
effect
ascophyllum
nodosum
linnaeu
le
joli
polyphenolrich
extract
dna
damag
oxid
stress
inflamm
level
eighti
particip
obes
consum
daili
eight
week
capsul
contain
mg
ascophyllum
nodosum
linnaeu
le
joli
polyphenolrich
extract
trial
period
obes
individu
present
result
significantli
distinct
placebo
decreas
lymphocyt
dna
damag
thu
work
suggest
longterm
consumpt
ascophyllum
nodosum
linnaeu
le
joli
polyphenol
rich
extract
could
benefici
sinc
could
potenti
decreas
risk
chronic
diseas
develop
obes
individu
line
research
allaert
et
al
found
compar
placebo
daili
intak
watersolubl
extract
ulva
lactuca
linnaeu
mg
per
kg
bodi
weight
three
month
significantli
improv
depress
state
subject
present
anhedonia
loss
sensit
come
feel
pleasur
placebo
group
particip
said
felt
improv
mood
versu
particip
ulva
lactuca
linnaeu
extract
group
statist
signific
differ
similarli
doctor
judg
subject
placebo
group
improv
versu
particip
ulva
lactuca
linnaeu
extract
group
author
point
identifi
compound
seawe
extract
respons
wit
effect
work
open
perspect
potenti
use
depress
therapi
tea
irhimeh
show
synergist
effect
daili
consumpt
brown
seawe
undaria
pinnatifida
harvey
suringar
g
spirulina
arthrospira
platensi
gomont
g
sinc
abl
increas
immun
respons
decreas
hiv
viral
fusionentri
replic
threemonth
period
furthermor
one
subject
continu
trial
month
report
decreas
hiv
viral
load
clinic
signific
improv
cellsml
despit
promis
result
note
sampl
size
work
small
n
make
gener
efficaci
research
imper
sinc
higher
level
serum
estradiol
associ
increas
risk
breast
cancer
develop
tea
et
al
report
daili
dose
g
alaria
esculenta
linnaeu
grevil
seven
week
abil
modul
serum
hormon
level
urinari
excret
estrogen
metabolit
phytoestrogen
diminish
breast
cancer
risk
women
conclus
studi
limit
small
number
particip
n
limit
statist
power
result
result
variou
clinic
trial
mention
point
consumpt
alga
particularli
brown
alga
benefici
human
health
howev
opinion
also
necessari
perform
identif
chemic
compound
respons
observ
effect
sever
studi
author
relat
observ
effect
constitu
seaweedextract
evalu
studi
fraction
rich
given
class
compound
substitut
identif
bioactiv
metabolit
health
effect
nevertheless
studi
also
import
establish
seawe
use
human
consumpt
last
year
secondari
metabolit
isol
macroalga
gain
grow
interest
shown
numer
articl
report
vivo
studi
compound
reach
clinic
trial
phase
although
mani
studi
present
result
qualiti
point
deserv
highlight
regard
major
consult
paper
futur
vivo
studi
especi
murin
model
increas
number
individu
test
group
increas
statist
power
find
also
refer
compound
alway
use
assess
real
efficaci
test
compound
frequent
lack
clariti
result
present
sever
public
also
downsid
interest
promis
studi
clinic
trial
studi
isol
compound
unfortun
scarc
could
due
divers
complic
like
obtain
necessari
approv
requir
start
studi
obtain
volunt
obtain
compound
enough
quantiti
addit
clinic
trial
aim
ascertain
extent
consumpt
alga
whole
extract
fraction
affect
human
health
particularli
effect
regard
obes
diabet
nonetheless
unfortun
mani
mention
studi
carri
small
popul
sampl
depriv
statist
power
anoth
seriou
flaw
numer
studi
address
alga
extract
fact
chemic
composit
mention
unknown
extrapol
effect
extract
alga
secondari
metabolit
way
guarante
andor
valid
knowledg
bioactiv
metabolit
activ
import
valid
alga
consumpt
despit
indic
limit
extract
clinic
trial
relev
qualit
safeti
evalu
opinion
studi
also
contribut
scientif
commun
interest
result
deeper
analysi
uncov
activ
metabolit
regardless
case
studi
repres
first
step
way
enhanc
alga
potenti
pharmaceut
sourc
new
compound
promis
properti
phlorotannin
show
great
pharmaceut
potenti
vivo
studi
indic
main
sourc
bioactiv
phlorotannin
alga
eisenia
ecklonia
ishig
genera
howev
observ
result
studi
geograph
distribut
studi
review
herein
show
phlorotannin
mechan
action
mainli
relat
modul
oxid
stress
inflammatori
cascad
phloroglucinol
eckol
dieckol
compound
wide
rang
applic
dieckol
antidyslipidemia
activ
must
highlight
effect
lovastatin
clinic
use
drug
hepatoprotect
activ
eckol
also
emphas
sinc
low
dose
mgkg
bw
need
concern
nonphlorotannin
group
compound
clear
great
varieti
interest
compound
mani
dire
need
test
bioactiv
effect
peptid
griffithsin
tridecapeptid
irliivlmpilma
kahalalid
f
highlight
arguabl
promis
nonphlorotannin
kahalalid
f
alreadi
move
beyond
vivo
stage
clinic
trial
wherea
tridecapeptid
level
activ
similar
clinic
drug
captopril
griffithsin
show
stun
result
varieti
anim
model
probabl
move
clinic
trial
stage
soon
contrast
promis
compound
halomon
neorogioltriol
exhibit
potent
relev
bioactiv
subject
clinic
trial
hope
discuss
present
paper
activ
interest
scientif
commun
studi
conduct
regard
fact
clinic
trial
isol
compound
scarc
carri
kahalalid
f
fucoxanthin
found
wherea
also
analyz
clinic
trial
involv
seawe
extract
conclud
consumpt
brown
alga
benefici
human
health
ascophyllum
nodosum
linnaeu
le
joli
lead
seawe
clinic
trial
